Sub: Allotment of equity shares of the Company to the eligible equity shareholders on rights basis.
Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
This is further to our intimations dated June 24, 2022, October 12, 2022 and October 18, 2022 informing the approval of the Rights Issue by the board of directors ("Board") and approval of the terms of the Rights Issue, record date and issue schedule by the Rights Issue Committee of the Board respectively.
In relation to the said Rights Issue and pursuant to the finalisation of the basis of allotment for the Rights Issue, approved by the designated stock exchange, i.e. BSE Limited on November 16, 2022, this is to inform that the Rights Issue Committee of the Board at its meeting held on November 16, 2022 (which commenced at 8.00 p.m. IST and concluded at 8.15 p.m. IST), has approved the allotment of 7,26,91,239 (Seven crore Twenty Six lakhs Ninety One thousand Two hundred and Thirty Nine) fully paid-up equity shares of the Company bearing distinctive numbers from 14,53,82,479 to 21,80,73,717 having a face value of Rs.1/- each in dematerialised form for cash at an issue price of Rs.55/- (Rupees Fifty Five Only) per equity share, i.e. at a premium of Rs.54/- (Rupees Fifty Four Only) per equity share, to the respective eligible equity shareholders (successful allottees) of the Company and / or renouncee(s) in terms of the letter of offer dated October 18, 2022.
Suven Life Sciences Limited
Registered Office: 8-2-334I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad - 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Post aforesaid allotment, the paid-up capital of the Company is Rs. 21,80,73,717/- (Rupees Twenty-One Crore Eighty Lacs Seventy-Three Thousand Seven Hundred and Seventeen Only) divided into 21,80,73,717 (Twenty-One Crore Eighty Lacs Seventy-Three Thousand Seven Hundred and Seventeen) fully paid-up equity shares having a face value of Rs.1/- (Rupees One only) each bearing ISIN INE495B01038.
This is for your information as also for the information of your members and the public at large.
Thanking You.
Yours faithfully,
For Suven Life Sciences Limited
SHRENIK SONI
Digitally signed by
SHRENIK SONI Date: 2022.11.16 20:19:21 +05'30'
Shrenik Soni
Company Secretary
Suven Life Sciences Limited
Registered Office: 8-2-334I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad - 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Suven Life Sciences Limited published this content on 16 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2022 15:18:05 UTC.
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.
SUVEN LIFE SCIENCES LIMITED 
